Charles River Laboratories International, Inc. (CRL) Financial Statements
Historical financial data — 41 statements covering FY2016–FY2025
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of anima...
Charles River Laboratories International, Inc.'s revenue decreased 0.9% year over year, from $4.05B to $4.02B.
Net income decreased 750.1% over the same period, from $22.2M to $-144.3M.
Over the 9-year period from FY2016 to FY2025, revenue grew by 139% in total.
Total debt remained relatively stable at $2.14B.
The debt-to-equity ratio stands at 0.68, indicating a moderate leverage profile.
Operating cash flow grew 0.4% to $737.6M.
Charles River Laboratories International, Inc. maintains a negative net profit margin of -3.6%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2023 | $3.12B+49.1% | $287.5M | $1.14B | $484.3M | $463.0M | $7.61B | $2.51B | $3.31B |
| Q1 FY2024 | $1.01B-67.5% | $73.0M | $344.8M | $126.0M | $129.9M | $8.15B | $2.66B | $3.64B |
| Q2 FY2024 | $2.04B+101.4% | $167.0M | $698.6M | $277.6M | $323.4M | $7.95B | $2.41B | $3.72B |
| Q3 FY2024 | $3.05B+49.6% | $236.7M | $1.05B | $395.0M | $575.2M | $8.00B | $2.33B | $3.78B |
| Q1 FY2025 | $984.2M-67.7% | $25.5M | $317.7M | $74.7M | $171.7M | $7.58B | $2.51B | $3.19B |
| Q2 FY2025 | $2.02B+104.9% | $77.8M | $674.8M | $174.8M | $376.3M | $7.56B | $2.33B | $3.35B |
| Q3 FY2025 | $3.02B+49.8% | $132.2M | $1.01B | $308.6M | $590.1M | $7.51B | $2.19B | $3.41B |
| Q1 FY2026 | $995.8M-67.0% | $-14.8M | $294.7M | $119.9M | $41.1M | $7.73B | $2.66B | $2.94B |